Clinical Trials Logo

Clinical Trial Summary

The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for treatment of AUD.


Clinical Trial Description

The investigators will evaluate the feasibility and safety of administering psilocybin to 10 patients diagnosed with AUD. Following informed consent, patients will be screened for eligibility as per in- and exclusion criteria and baseline values will be recorded as per outcome measures. All patients will receive a single administration of 25 mg of psilocybin. As per safety guidelines patients will be monitored the entire dosing session by study staff familiar with the psychedelic effects of psilocybin. In addition, the patients will meet before and after the dosing session with a psychologist connected to the study for preparation and post-session debriefing, respectively. During dosing session, the investigators will collect blood plasma psilocin levels in order to establish pharmacokinetics and an estimated brain 5-HT2AR occupancy. When the effects of psilocybin subside, the investigators will ask the patients to fill out questionnaires encapsulating the psychedelic experience. One week after drug administration the patients are required to meet for an end-of-study assessment of outcome measures including adverse events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04718792
Study type Interventional
Source Psychiatric Centre Rigshospitalet
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 9, 2023
Completion date June 21, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04927364 - Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder N/A
Active, not recruiting NCT04618653 - Comprehensive Process Model of AA-related Behavior Change
Recruiting NCT05471154 - Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders N/A
Completed NCT05021640 - Study of DCR-AUD in Healthy Volunteers Phase 1
Not yet recruiting NCT05064228 - Mobile Rewarding Activity Centered Treatment N/A
Completed NCT04958655 - Mental Imagery Intervention for Alcohol Craving N/A
Recruiting NCT05252221 - Alcohol Telemedicine Consultation in Primary Care (ATC) N/A
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Completed NCT04639895 - Cognitive Rehabilitation Through Personalized Virtual Reality and Paper-and-pencil Interventions in the Alcohol Use Disorder Treatment. N/A
Completed NCT02911285 - NAC for Treating Comorbid PTSD and SUD Phase 2
Recruiting NCT04598399 - Comparison of the Effectiveness of Two Psycho-physical Interventions: Mindfulness Based Relapse Prevention (MBRP) and Unguided Meditative Relaxation in Patients With Alcohol Use Disorder N/A
Completed NCT04827056 - Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study Phase 1
Completed NCT04974645 - Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use N/A
Recruiting NCT05992272 - Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer
Completed NCT04229095 - Medication Development in Alcoholism: Suvorexant Versus Placebo Phase 2
Recruiting NCT05534568 - The Oklahoma Parent-Child Assistance Program N/A
Completed NCT04925570 - The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use Phase 2
Active, not recruiting NCT05492942 - Records for Alcohol Care Enhancement N/A
Recruiting NCT05015881 - Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder Phase 2/Phase 3
Active, not recruiting NCT05120856 - AAT-App Outpatient Trial N/A